Coherus Biosciences, Inc. announced submission to the FDA of its biologics license application (BLA) for CHS-1701, a pegfilgrastim (Neulasta®) biosimilar candidate. Pegfilgrastim is used to prevent or treat neutropenia, a disorder wherein a patient is more susceptible to infection due to chemotherapy. Coherus supported its 351(k) application with similarity data…